menu
    • menu
    [{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Piracetam","moa":"Ach receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Moksha8 Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Moksha8 Pharmaceuticals \/ UCB Pharma S.A"}]

    Find Clinical Drug Pipeline Developments & Deals for Breinox, Dinagen, Lucetam, Nootropil, Nootropyl, Oikamid, and many others

    Menu

    Breinox, Dinagen, Lucetam, Nootropil, Nootropyl, Oikamid, and many others

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Piracetam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            M8 Pharmaceuticals and UCB Partner for Central Nervous System and Respiratory Portfolio in Mexico

                            Details : According to IQVIA, the portfolio has annual sales of approximately $26 million dollars and includes drugs such as: ATARAX®, NOOTROPIL®, XUZAL®, and VIRLIX®.

                            Product Name : Nootropil

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Piracetam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth